GlobeNewswire by notified

iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

Share

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update.

To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from the News and Events page of the Company’s website at https://investors.iteostherapeutics.com/news-and-events/events. The archived webcast will be available approximately two hours after the completion of the event and for one week following the call.

To pre-register for the event, please use the following link to receive access details via email:
https://www.incommglobalevents.com/registration/q4inc/9144/iteos-therapeutics-q3-2021-earnings-conference-call/.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PubMatic Executive Peter Barry Promoted to Global Role of VP Addressability2.12.2021 22:00:00 CET | Press release

Barry to relocate to New York to lead PubMatic’s audience data business NO-HEADQUARTERS/REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), a sell-side platform that delivers superior outcomes for digital advertising, today announced it has appointed Regional Director, Australia and New Zealand & Head of Audience, APAC, Peter Barry to a global role, naming him VP of Addressability. Barry, who joined the company in 2016, will relocate from Sydney to New York for the new role. He will provide overall leadership across multiple cross functional teams and lead efforts with publishers to ensure they monetise their inventory and drive better outcomes for advertisers and data partners. Barry has been responsible for rolling out the company’s Addressability Suite across APAC, and working with leading data and identity partners in the region. PubMatic’s Addressability Suite includes Audience Encore, which enables data companies, publishers, and advertisers to buy an

PubMatic Executive Peter Barry Promoted to Global Role of VP Addressability2.12.2021 22:00:00 CET | Press release

Barry to relocate to New York to lead PubMatic’s audience data business NO-HEADQUARTERS/REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), a sell-side platform that delivers superior outcomes for digital advertising, today announced it has appointed Regional Director, Australia and New Zealand, Peter Barry to a global role, naming him VP of Addressability. Barry, who joined the company in 2016, will relocate from Sydney to New York for the new role. He will provide overall leadership across multiple cross functional teams and lead efforts with publishers to ensure they monetise their inventory and drive better outcomes for advertisers. Barry has been responsible for rolling out the company’s Addressability Suite across APAC, and working with leading data and identity partners in the region. PubMatic’s Addressability Suite includes Audience Encore, which enables data companies, publishers, and advertisers to buy and sell first-party data and utilize it to c

Bombardier Marks Dual Celebration – NetJets Accepts First Global 7500 Business Jet as Bombardier Delivers 1,000th Global Aircraft2.12.2021 20:05:00 CET | Press release

Delivery of industry’s longest-range business jet marks the first of 20 Global 7500 aircraft to join the NetJets fleet Global 7500 aircraft continues to garner significant interest from customers who value features such as the largest and most unique cabin, innovative technology, unparalleled performance and the smoothest ride MONTRÉAL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bombardier announced today the delivery of the 1,000th Global aircraft. The major milestone was reached as the NetJets team led by Patrick Gallagher, President, Sales, Marketing and Services, took delivery of the private aviation company’s first Global 7500 business jet. The addition of a Global 7500 aircraft to the NetJets fleet redefines its large-cabin, long-range offering, and elevates the choice of travel options for its international Owners. With a 7,700 nm (14,260 km) range, NetJets Owners will be able to fly from New York to Beijing or San Francisco to Sydney without refueling stops. The Global 7500 aircraft is

Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma2.12.2021 19:00:00 CET | Press release

Designation covers UV1 in Metastatic Melanoma as sole agent or part of combination Seven-year market exclusivity after regulatory approval, if received Oslo, 2December2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on therapy to checkpoint inhibitors ipilimumab and nivolumab, is currently being studied as first-line treatment for metastatic melanoma in a Phase II trial named INITIUM. The FDA Office of Orphan Products Development (OOPD) supports and advances the development and evaluation of new treatments for rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain benefits, including seven-year market exclusivity upon regulatory approval if received, exemption fro

Mandalay Resources Corporation säljer Cerro Bayo-gruvan till Equus Mining2.12.2021 18:49:34 CET | Pressemelding

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att meddela att man har slutfört den tidigare aviserade försäljningen av Cerro Bayo-gruvan i Region XI i södra Chile (se Mandalays pressmeddelanden från den 12 oktober 2021 och den 8 oktober 2019). I enlighet med transaktionen förvärvade Equus Mining Limited (”Equus”) Cerro Bayo-gruvan, inklusive dess gruvanläggningar, -tillgångar och -infrastruktur samt en bearbetningsanläggning på 1 500 ton per dag, i utbyte mot 587 502 438 stamaktier i Equus. Mandalay får också en nettoprovision på smältning på 2,25 % på produktionen från Cerro Bayo-gruvan när gruvan har producerat minst 50 000 uns guldekvivalent, som omfattas av en återköpsoption till förmån för Equus. Bolaget förblir ansvarigt för 50 % av de godkända kostnaderna för stängningen av anläggningen vid Cerro Bayo. Dessutom kommer Equus att utse Ryan Austerberry, Mandalays General Manager för Costerfi

Ultimovacs ASA: Mandatory notification of trade by primary insider2.12.2021 16:30:00 CET | Press release

Oslo, 2 December 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 107.60 per share. Following this transaction, Carlos de Sousa and closely related parties hold 15,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 20211221 - Ultimovacs Notification of trade - KRT-1500

Connecterra and Lely Announce Strategic Partnership2.12.2021 15:05:00 CET | Press release

Following the completion of a successful pilot, the two companies will deepen their collaboration and commercial relationship Amsterdam, The Netherlands, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Today Dutch-based startup, Connecterra, a world leader in using artificial intelligence to deliver insights to farmers, and Lely, the global leading supplier of robotics and management systems for dairy farming, announced the start of a robust co-development and commercial partnership. The announcement follows a pilot with Lely’s Digital Farming Group. The pilot program was designed to test an integration between Lely Horizon and Connecterra’s artificial intelligence platform, Ida. The successful effort has resulted in commitments to several strategic initiatives. As a first step in the agreement, Lely will now license Ida Enterprise for use in their farm management system Lely Horizon. “We believe that digitization of dairy farming is key and needs to be handled with care. Integrating with partners l